Non-small cell lung cancer: PD-L1 access test for pembrolizumab gets MBS approval


The Medical Services Advisory Committee (MSAC) has ‘foreshadowed its support’ for a new MBS item for PD-L1 testing to help determine eligibility for PBS-subsidised pembrolizumab (Keytruda) as a first line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The application was part of a co-dependent resubmission from MSD Australia and ...

Already a member?

Login to keep reading.


OR
© 2018 the limbic